{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["afatinib"]],"indication":"EGFR-mutated advanced non-small-cell lung cancer","name":"LUX-Lung 2","nct_id":"NCT00525148","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lux-lung-2-nct00525148. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs. After protocol amendment 2 (17 Dec 2008), the starting dose of BIBW 2992 was reduced to a medium dose, with 2 possible dose reductions if needed after discontinuation due to drug-related AEs.","label":"BIBW 2992","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2015-08","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":129,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"BIBW 2992","otherNames":[],"type":"DRUG"}],"last_update":"2016-09-16","lead_sponsor":"Boehringer Ingelheim","official_title":"LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2010-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response (OR) as Determined by RECIST 1.0","timeFrame":"Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months."}],"references":[{"citation":"Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. doi: 10.1016/S1470-2045(15)00026-1. Epub 2015 Jun 4.","pmid":"26051236","type":"DERIVED"},{"citation":"Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. doi: 10.1016/S1470-2045(12)70086-4. Epub 2012 Mar 26.","pmid":"22452895","type":"DERIVED"}],"start_date":{"date":"2007-08"},"study_type":"INTERVENTIONAL","title":"LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations","url":"https://clinicaltrials.gov/study/NCT00525148"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lux-lung-2-nct00525148"}